Heparin-based, injectable microcarriers for controlled delivery of interleukin-13 to the brain

Research output: Contribution to journal › Research article › Contributed › peer-review

Contributors

  • Lucas Schirmer - , Leibniz Institute of Polymer Research Dresden (Author)
  • Chloé Hoornaert - , University of Antwerp (Author)
  • Debbie Le Blon - , University of Antwerp (Author)
  • Dimitri Eigel - , Chair of Biofunctional Polymer Materials, Leibniz Institute of Polymer Research Dresden (Author)
  • Catia Neto - , Cardiff University (Author)
  • Mark Gumbleton - , Cardiff University (Author)
  • Petra B. Welzel - , Leibniz Institute of Polymer Research Dresden (Author)
  • Anne E. Rosser - , Cardiff University (Author)
  • Carsten Werner - , Center for Regenerative Therapies Dresden, Chair of Biofunctional Polymer Materials, Leibniz Institute of Polymer Research Dresden (Author)
  • Peter Ponsaerts - , University of Antwerp (Author)
  • Ben Newland - , Leibniz Institute of Polymer Research Dresden, Cardiff University (Author)

Abstract

Interleukin-13 (IL-13) drives cells of myeloid origin towards a more anti-inflammatory phenotype, but delivery to the brain remains problematic. Herein, we show that heparin-based cryogel microcarriers load high amounts of IL-13, releasing it slowly. Intra-striatal injection of loaded microcarriers caused local up-regulation of ARG1 in myeloid cells for pro-regenerative immunomodulation in the brain.

Details

Original languageEnglish
Pages (from-to)4997-5004
Number of pages8
JournalBiomaterials science
Volume8
Issue number18
Publication statusPublished - 21 Sept 2020
Peer-reviewedYes

External IDs

PubMed 32931543
ORCID /0000-0003-0189-3448/work/161890290

Keywords

ASJC Scopus subject areas